ALNY

399.40

5.47% -23.10

Dopo l'orario di chiusura: 399.40

Alnylam Pharmaceuticals Inc (ALNY)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ALNY Giù? Forum Previsione

Precedente Chiudi:

$422.50

Aprire:

$420.18

Volume 24 ore:

1.40M

Relative Volume:

1.12

Capitalizzazione di mercato:

$52.77B

Reddito:

$3.21B

Utile/perdita netta:

$43.57M

Rapporto P/E:

1,660.71

EPS:

0.2405

Flusso di cassa netto:

$221.36M

1 W Prestazione:

+0.44%

1M Prestazione:

-7.12%

6M Prestazione:

+25.80%

1 anno Prestazione:

+66.04%

Intervallo 1D:

$393.48

$425.19

Intervallo di 1 settimana:

$383.84

$427.05

Portata 52W:

$205.87

$495.55

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Nome

Alnylam Pharmaceuticals Inc

Settore

Healthcare (1113)

Industria

Biotechnology (621)

Telefono

(617) 551-8200

Indirizzo

675 WEST KENDALL STREET, CAMBRIDGE, MA

Dipendente

2,230

Cinguettio

@alnylam

Prossima data di guadagno

2024-10-31

Ultimi documenti SEC

ALNY's Discussions on Twitter

Confronta ALNY con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ALNY Alnylam Pharmaceuticals Inc	399.40	55.82B	3.21B	43.57M	221.36M	0.2405
VRTX Vertex Pharmaceuticals Inc	469.68	122.84B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	801.01	85.37B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	795.57	50.67B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	170.27	37.54B	447.02M	-1.18B	-906.14M	-6.1812

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-07	Ripresa	Oppenheimer	Outperform
2025-08-04	Aggiornamento	Oppenheimer	Perform → Outperform
2025-08-04	Aggiornamento	Wolfe Research	Underperform → Peer Perform
2025-07-30	Ripresa	Raymond James	Outperform
2025-07-21	Iniziato	Truist	Buy
2025-03-31	Iniziato	Redburn Atlantic	Buy
2025-03-24	Aggiornamento	JP Morgan	Neutral → Overweight
2024-11-12	Downgrade	Wolfe Research	Peer Perform → Underperform
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-08-16	Aggiornamento	Goldman	Neutral → Buy
2024-02-16	Downgrade	Goldman	Buy → Neutral
2024-02-15	Iniziato	Wolfe Research	Peer Perform
2023-12-08	Iniziato	Wells Fargo	Equal Weight
2023-10-11	Downgrade	Oppenheimer	Outperform → Perform
2023-09-29	Iniziato	Raymond James	Outperform
2023-05-05	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2023-04-26	Iniziato	SMBC Nikko	Neutral
2023-03-21	Iniziato	Bernstein	Outperform
2023-01-18	Iniziato	Canaccord Genuity	Buy
2022-09-09	Ripresa	Morgan Stanley	Equal-Weight
2022-07-13	Iniziato	Cantor Fitzgerald	Neutral
2022-06-27	Downgrade	Guggenheim	Buy → Neutral
2022-06-07	Iniziato	William Blair	Outperform
2022-04-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2022-03-01	Iniziato	Citigroup	Buy
2022-02-03	Aggiornamento	Guggenheim	Neutral → Buy
2022-01-03	Aggiornamento	Piper Sandler	Neutral → Overweight
2021-11-22	Aggiornamento	Goldman	Neutral → Buy
2021-11-22	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2021-11-01	Aggiornamento	Oppenheimer	Perform → Outperform
2021-10-04	Aggiornamento	UBS	Neutral → Buy
2021-08-04	Downgrade	Piper Sandler	Overweight → Neutral
2021-02-22	Downgrade	Guggenheim	Buy → Neutral
2021-02-12	Downgrade	Citigroup	Buy → Neutral
2021-02-12	Reiterato	H.C. Wainwright	Buy
2021-01-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
2020-09-30	Ripresa	Berenberg	Hold
2020-09-08	Iniziato	Citigroup	Buy
2020-08-11	Downgrade	Oppenheimer	Outperform → Perform
2020-05-13	Iniziato	RBC Capital Mkts	Sector Perform
2020-05-07	Downgrade	JP Morgan	Overweight → Neutral
2020-04-24	Ripresa	Evercore ISI	Outperform
2020-03-19	Iniziato	Berenberg	Buy
2019-12-19	Reiterato	Chardan Capital Markets	Buy
2019-11-20	Iniziato	Oppenheimer	Outperform
2019-11-13	Iniziato	BofA/Merrill	Buy
2019-05-23	Ripresa	Goldman	Neutral
2019-04-12	Iniziato	Evercore ISI	Outperform
2019-03-06	Aggiornamento	Evercore ISI	In-line → Outperform
2019-03-05	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2019-01-23	Iniziato	UBS	Neutral
2018-10-01	Iniziato	Cantor Fitzgerald	Overweight
2018-08-13	Reiterato	Stifel	Buy
2018-08-07	Aggiornamento	Stifel	Hold → Buy
2018-05-04	Reiterato	Stifel	Hold
2018-03-28	Iniziato	Evercore ISI	In-line

Mostra tutto

Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie

Jan 08, 2026

Can Alnylam Pharmaceuticals Inc. stock beat market expectations this quarterJuly 2025 Retail & Technical Pattern Based Buy Signals - ulpravda.ru

Jan 08, 2026

Is Alnylam Pharmaceuticals Inc. (DUL) stock testing key supportEarnings Risk Summary & Capital Efficient Trade Techniques - ulpravda.ru

Jan 08, 2026

A Look At Alnylam Pharmaceuticals (ALNY) Valuation As It Previews New Five Year Plan And Revenue Outlook - simplywall.st

Jan 08, 2026

Is Alnylam Pharmaceuticals Inc. stock safe for conservative investorsWeekly Trend Summary & Reliable Volume Spike Alerts - ulpravda.ru

Jan 08, 2026

Europe Gene Therapy Market to hit US$ 8,780.77 Million by 2033 | - openPR.com

Jan 08, 2026

Jan 07, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) Seems To Use Debt Quite Sensibly - Yahoo Finance

Jan 07, 2026

Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical - GlobeNewswire Inc.

Jan 07, 2026

Jan 06, 2026

Will Alnylam Pharmaceuticals Inc. stock remain a Wall Street favorite2026 world cup usa national team group stage young talents build up play winner prediction statistical analysis - ulpravda.ru

Jan 06, 2026

Bernstein lowers Alnylam stock price target to $491 on slowing Amvuttra sales - Investing.com UK

Jan 06, 2026

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): A GARP Candidate with Strong Growth and Fair Valuation - Chartmill

Jan 06, 2026

Nucleic Acid Therapeutics Market to Reach US$ 14.42 Billion - openPR.com

Jan 06, 2026

Jan 05, 2026

Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference - Business Wire

Jan 05, 2026

Generali Asset Management SPA SGR Has $1.48 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Jan 05, 2026

Jan 04, 2026

Western Financial Corp CA Invests $1.24 Million in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Jan 04, 2026

Jan 02, 2026

The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500 - FinancialContent

Jan 02, 2026

Dec 31, 2025

Aug Closing: Why Alnylam Pharmaceuticals Inc. stock could be next big winnerJuly 2025 Action & Risk Controlled Swing Alerts - moha.gov.vn

Dec 31, 2025

Dec 30, 2025

Alnylam Pharmaceuticals (STU:DUL) EV-to-OCF : 207.04 (As of Dec. 28, 2025) - GuruFocus

Dec 28, 2025

Dec 27, 2025

Highland Capital Management LLC Buys Shares of 4,569 Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Dec 27, 2025

Dec 26, 2025

Cns Specific Antisense Oligonucleotide MarketForecast - openPR.com

Dec 26, 2025

Dec 25, 2025

Massachusetts lands rare manufacturing wins from Moderna and Alnylam amid tariff push - The Business Journals

Dec 25, 2025

Dec 23, 2025

Brighton Jones LLC Acquires 3,909 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Dec 23, 2025

Alnylam Pharmaceuticals (ALNY) Valuation Check After NASDAQ-100 Entry and $250m Manufacturing Expansion - simplywall.st

Dec 23, 2025

Dec 22, 2025

Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23) - ts2.tech

Dec 22, 2025

Here’s why Alnylam Pharmaceuticals (ALNY) surged in Q3 - MSN

Dec 22, 2025

Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook - ts2.tech

Dec 22, 2025

Alnylam Pharmaceuticals, Inc.(NasdaqGS: ALNY) added to NASDAQ-100 Index - marketscreener.com

Dec 22, 2025

RNAi (RNA Interference) Technology Market to Reach US$ 6.63 - openPR.com

Dec 22, 2025

Dec 21, 2025

Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open - ts2.tech

Dec 21, 2025

Bear Alert: Why Alnylam Pharmaceuticals Inc. stock could be next big winnerQuarterly Risk Review & Low Risk Profit Maximizing Plans - Улправда

Dec 21, 2025

118,800 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Congress Asset Management Co. - MarketBeat

Dec 21, 2025

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Dec 21, 2025

Dec 20, 2025

PeptiDream (TSE:4587): Assessing Valuation After New IL-17 Oral Candidate and Alnylam siRNA Milestone - Yahoo Finance

Dec 20, 2025

Market Moves: Can Alnylam Pharmaceuticals Inc. stock beat market expectations this quarterQuarterly Profit Review & AI Driven Price Forecasts - ulpravda.ru

Dec 20, 2025

Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025 - ts2.tech

Dec 20, 2025